RARE on XNAS, Health Care, Ultragenyx Pharmaceutical Inc., job postings
Measures activity, not value. Not investment advice.
Revenue grew 16% to $730.3M but the stock fell 47% over 12 months while 23% of shares are shorted.
BadNet loss of $523.6M over the last 12 months
BadInstitutional holders fell 13% to 263 from 304
Written by AI from the data on this page, 22 Nov 2026. Not investment advice.
Profile and fundamentals
From its SEC filings, 12 months to 30 Sep 2026
Ultragenyx Pharmaceutical Inc is a USA-based biopharmaceutical company. The company identifies, acquires, develops, and commercializes novel products for the treatment of serious, rare, and ultra-rare diseases, with a focus on debilitating genetic conditions. Its medicine portfolio includes Crysvita, Dojolvi, and Mepsevii. Crysvita is indicated for the treatment of X-linked hypophosphatemia (XLH) in adult and pediatric patients aged one year and older. Mepsevii is indicated for pediatric and adult patients for the treatment of Mucopolysaccharidosis VII. The company operates across North America, Latin America, Europe, the Middle East and Africa, and Asia-Pacific, with the majority of its revenue generated from North America.
expected around 11 Jan 2027 (an estimate: a year ago it reported on 12 Jan 2026)
Revenue and net income per quarter. Quarter to 30 Sep 2026: revenue $173.0M, net loss $118.0M.
31 Dec 2021RevenueNet incomeNet losstallest bar $245.1M30 Sep 2026
See the numbers
Quarter to
Revenue
Net income
30 Sep 2026
$173.0M
-$118.0M
30 Jun 2026
$214.0M
-$92.0M
31 Mar 2026
$136.0M
-$185.0M
31 Dec 2025
$207.3M
-$128.6M
30 Sep 2025
$159.9M
-$180.4M
30 Jun 2025
$166.5M
-$115.0M
31 Mar 2025
$139.3M
-$151.1M
31 Dec 2024
$164.9M
-$133.4M
30 Sep 2024
$139.5M
-$133.5M
30 Jun 2024
$147.0M
-$131.6M
31 Mar 2024
$108.8M
-$170.7M
31 Dec 2023
$127.4M
-$123.2M
30 Sep 2023
$98.1M
-$159.6M
30 Jun 2023
$108.3M
-$159.8M
31 Mar 2023
$100.5M
-$164.0M
31 Dec 2022
$103.3M
-$151.8M
30 Sep 2022
$90.7M
-$245.1M
30 Jun 2022
$89.3M
-$158.2M
31 Mar 2022
$79.9M
-$152.3M
31 Dec 2021
$83.4M
-$122.5M
Fundamentals, 12 months to 30 Sep 2026
Measure
Latest
Year before
Peer median
RevenueiSales over the last 12 months reported.
$730.3M
$630.9M
Revenue growthiRevenue of the last 12 months compared with the 12 months before.
+16%
+11%
Net incomeiProfit after all costs and taxes over the last 12 months reported. Negative is a loss.
-$523.6M
-$579.4M
EPS (diluted)iEarnings per share: net income divided by the shares, counting options and convertibles. Left blank when the figures as filed do not fit today's share count (after a split).
-$5.18
-$5.93
Gross marginiWhat is left of each dollar of sales after the direct cost of making the product or service.
–
–
73.2%
Operating marginiOperating income as a share of sales: profit from the business before interest and taxes.
-64.0%
-86.3%
-25.0%
Net marginiNet income as a share of sales: what the owners keep of each dollar sold.
-71.7%
-91.8%
-18.2%
Return on equityiNet income of the last 12 months divided by shareholders' equity (the average of the latest balance sheet and the one a year earlier): the profit made on the owners' money.
–
-58.8%
Free cash flowiCash from operations minus capital spending over the last 12 months: cash the business produced.
–
-$450.6M
CashiCash, cash equivalents and short-term investments on the latest balance sheet.
$266.0M
$425.7M
DebtiShort- and long-term borrowings on the latest balance sheet. Operating leases are not counted.
$0
$0
Net debtiDebt minus cash. Negative means the company holds more cash than it owes (net cash).
-$266.0M (net cash)
-$425.7M
Debt to equityiDebt divided by shareholders' equity on the latest balance sheet: how much is borrowed for each dollar the owners have in the company. Blank when equity is negative.
–
0.0
Book value per shareiShareholders' equity (assets minus liabilities) on the latest balance sheet divided by the shares outstanding.
–
P/EiPrice to earnings: market cap divided by net income of the last 12 months. What investors pay for one dollar of yearly profit. Blank when the company made a loss.
loss
19.3
P/SiPrice to sales: market cap divided by revenue of the last 12 months.
2.3
5.0
EV/SalesiEnterprise value (market cap plus debt minus cash) divided by revenue of the last 12 months.
1.9
5.0
P/BiPrice to book: market cap divided by shareholders' equity on the latest balance sheet. Blank when equity is negative.
–
2.0
Latest = 12 months to 30 Sep 2026; balance-sheet lines at its end. Peer median: companies in the same industry (SIC code), or the sector when the industry is small.
Peers nearest by market cap, its own industry first
Revenue growth iSales in the latest reported quarter compared with the same quarter a year earlier.
+8.2%
$173.0M vs $159.9M (quarter ended 30 Sep 2026)
Insider buy/sell iShares the company's insiders (directors, officers and owners of 10% or more) bought minus what they sold on the open market in the last 90 days, from their Form 4 filings.
-$128K
bought $0, sold $128K
Institutional holders iThe number of institutional investment managers (13F filers: funds, pensions, asset managers) reporting the stock, compared with the quarter before. 13F reports are public 45 days after quarter end and show long positions only.
-13%
263 13F filers vs 304
Institutional ownership iShares held by 13F filers at the latest quarter end, divided by the shares outstanding in the company's latest filing. Above 100% usually means a stale share count or double counting, and is marked.
over 100%
102.7M shares held by 13F filers (30 Sep 2026) of 101.9M outstanding (29 Oct 2026); above 100%: the share count is probably stale
Short interest iShares sold short and not yet bought back, divided by the shares outstanding in the company's latest filing. From FINRA's latest short interest report: FINRA reports twice a month and publishes 7 business days after the settlement date. Above 100% means a stale share count, and is marked.
23%
23.6M shares sold short (30 Oct 2026) of 101.9M outstanding (29 Oct 2026)
Days to cover iShort interest divided by the stock's average daily trading volume, as FINRA publishes it: how many days of normal trading it would take short sellers to buy back every share. Latest report.
8.3
23.6M shares sold short (30 Oct 2026) divided by the stock's average daily volume, as FINRA publishes it
Short interest change iHow the number of shares sold short changed between FINRA's two latest reports, about two weeks apart.
+17%
20.1M shares sold short in the report before, 23.6M on 30 Oct 2026
Short sale volume iShare of the stock's latest daily volume on FINRA-reported off-exchange venues that was sold short. Market makers sell short routinely, so 40% to 50% is normal; compare it with the company's own 1-year average in the cell's details. A daily flow, not short interest.
40%
40% of off-exchange volume on 20 Nov 2026 was short sales; 1-year average 43%
Lobbying iWhat the company reported spending on federal lobbying over the last four quarters.
$1.2M
4 quarters
News iArticles about the company published in the last 7 days, from our Google News collection (one search per company, every half hour). Blank when we do not collect news for this company.
18
18 articles in the last 7 days; its usual week has 3.5 (the median of the 26 weeks before).
News vs usual iArticles in the last 7 days divided by the company's usual week: the median week of the 26 weeks before. Blank when the usual week has fewer than one article.
5.1×
18 articles in the last 7 days; its usual week has 3.5.
Price $16.48 on 20 Nov 2026, -47% over 12 months (12-month range $12.88 to $36.54)
Sharp change
8-K and other filings
Lobbying filing
Insider net buying (open market). Insiders sold a net $3.8M in the last 12 months (the 12 months before: -$8.2M).H-1B/E-3 applications certified. H-1B/E-3 applications certified: 5 published in the last 12 months, -38% on the 12 months before.Revenue per quarter. Revenue $173.0M in the latest quarter, +8.2% on a year earlier.Capital spending per quarter. Capital spending $1.0M in the latest quarter, -24% on a year earlier.Institutional holders (13F filers). 263 13F filers reported holding it in the latest 13F quarter, -7.4% on a year earlier.Lobbying spend. Lobbying spend: $1.2M published in the last 12 months, +72% on the 12 months before.
Every point sits on the day the fact became public (filing acceptance or publication), not the day it happened; prices through 20 Nov 2026. Hover or tap a marker for the fact; click it for the evidence or the source. No data here for: federal obligations, workers in warn layoff notices.
Quarter ended 31 Dec 2021: $83.4M, -8.9% on a year earlier; public on 16 Feb 2022
Quarter ended 31 Mar 2022: $79.9M, -20% on a year earlier; public on 7 May 2022
Quarter ended 30 Jun 2022: $89.3M, +2.7% on a year earlier; public on 30 Jul 2022
Quarter ended 30 Sep 2022: $90.7M, +11% on a year earlier; public on 4 Nov 2022
Quarter ended 31 Dec 2022: $103.3M, +24% on a year earlier; public on 18 Feb 2023
Quarter ended 31 Mar 2023: $100.5M, +26% on a year earlier; public on 6 May 2023
Quarter ended 30 Jun 2023: $108.3M, +21% on a year earlier; public on 5 Aug 2023
Quarter ended 30 Sep 2023: $98.1M, +8.1% on a year earlier; public on 4 Nov 2023
Quarter ended 31 Dec 2023: $127.4M, +23% on a year earlier; public on 22 Feb 2024
Quarter ended 31 Mar 2024: $108.8M, +8.3% on a year earlier; public on 4 May 2024
Quarter ended 30 Jun 2024: $147.0M, +36% on a year earlier; public on 3 Aug 2024
Quarter ended 30 Sep 2024: $139.5M, +42% on a year earlier; public on 7 Nov 2024
Quarter ended 31 Dec 2024: $164.9M, +29% on a year earlier; public on 20 Feb 2025
Quarter ended 31 Mar 2025: $139.3M, +28% on a year earlier; public on 8 May 2025
Quarter ended 30 Jun 2025: $166.5M, +13% on a year earlier; public on 7 Aug 2025
Quarter ended 30 Sep 2025: $159.9M, +15% on a year earlier; public on 6 Nov 2025
Quarter ended 31 Dec 2025: $207.3M, +26% on a year earlier; public on 19 Feb 2026
Quarter ended 31 Mar 2026: $136.0M, -2.4% on a year earlier; public on 7 May 2026
Quarter ended 30 Jun 2026: $214.0M, +29% on a year earlier; public on 6 Aug 2026
Quarter ended 30 Sep 2026: $173.0M, +8.2% on a year earlier; public on 5 Nov 2026
Capital spending per quarter
Quarter ended 31 Dec 2021: $16.0M, -27% on a year earlier; public on 16 Feb 2022
Quarter ended 31 Mar 2022: $32.2M, +96% on a year earlier; public on 7 May 2022
Quarter ended 30 Jun 2022: $30.9M, +54% on a year earlier; public on 30 Jul 2022
Quarter ended 30 Sep 2022: $26.0M, +27% on a year earlier; public on 4 Nov 2022
Quarter ended 31 Dec 2022: $27.0M, +68% on a year earlier; public on 18 Feb 2023
Quarter ended 31 Mar 2023: $25.0M, -22% on a year earlier; public on 6 May 2023
Quarter ended 30 Jun 2023: $13.9M, -55% on a year earlier; public on 5 Aug 2023
Quarter ended 30 Sep 2023: $3.7M, -86% on a year earlier; public on 4 Nov 2023
Quarter ended 31 Dec 2023: $1.6M, -94% on a year earlier; public on 22 Feb 2024
Quarter ended 31 Mar 2024: $3.2M, -87% on a year earlier; public on 4 May 2024
Quarter ended 30 Jun 2024: $2.0M, -86% on a year earlier; public on 3 Aug 2024
Quarter ended 30 Sep 2024: $1.6M, -56% on a year earlier; public on 7 Nov 2024
Quarter ended 31 Dec 2024: $654K, -59% on a year earlier; public on 20 Feb 2025
Quarter ended 31 Mar 2025: $1.3M, -59% on a year earlier; public on 8 May 2025
Quarter ended 30 Jun 2025: $2.5M, +22% on a year earlier; public on 7 Aug 2025
Quarter ended 30 Sep 2025: $1.3M, -21% on a year earlier; public on 6 Nov 2025
Quarter ended 31 Mar 2026: $1.0M, -24% on a year earlier; public on 7 May 2026
Institutional holders (13F filers)
31 Dec 2021 report: 217; public on 14 Feb 2022
31 Mar 2022 report: 224; public on 16 May 2022
30 Jun 2022 report: 207; public on 15 Aug 2022
30 Sep 2022 report: 211; public on 14 Nov 2022
31 Dec 2022 report: 209; public on 14 Feb 2023
31 Mar 2023 report: 215; public on 15 May 2023
30 Jun 2023 report: 221; public on 14 Aug 2023
30 Sep 2023 report: 205; public on 14 Nov 2023
31 Dec 2023 report: 224; public on 14 Feb 2024
31 Mar 2024 report: 260; public on 15 May 2024
30 Jun 2024 report: 258; public on 14 Aug 2024
30 Sep 2024 report: 288; public on 14 Nov 2024
31 Dec 2024 report: 303; public on 14 Feb 2025
31 Mar 2025 report: 290; public on 15 May 2025
30 Jun 2025 report: 301; public on 14 Aug 2025
30 Sep 2025 report: 284; public on 14 Nov 2025
31 Dec 2025 report: 275; public on 17 Feb 2026
31 Mar 2026 report: 288; public on 15 May 2026
30 Jun 2026 report: 304; public on 14 Aug 2026
30 Sep 2026 report: 263; public on 16 Nov 2026
Lobbying spend
Quarter from 1 Jan 2022: $100K published
Quarter from 1 Apr 2022: $50K published
Quarter from 1 Jul 2022: $50K published
Quarter from 1 Oct 2022: $50K published
Quarter from 1 Jan 2023: $50K published
Quarter from 1 Apr 2023: $50K published
Quarter from 1 Jul 2023: $60K published
Quarter from 1 Oct 2023: $40K published
Quarter from 1 Jan 2024: $79K published
Quarter from 1 Apr 2024: $250K published
Quarter from 1 Jul 2024: $30K published
Quarter from 1 Oct 2024: $80K published
Quarter from 1 Jan 2025: $110K published
Quarter from 1 Apr 2025: $330K published
Quarter from 1 Jul 2025: $140K published
Quarter from 1 Oct 2025: $140K published
Quarter from 1 Jan 2026: $130K published
Quarter from 1 Jul 2026: $830K published
Quarter from 1 Oct 2026: $280K published
What is unusual now
Nothing unusual in the last 90 days: no change appeared. Its most unusual measure now is lobbying spend reported (quarter) at $280K (30 Sep 2026), 2.0× its normal reading; higher than 89% of its own history. Two or more unrelated kinds of activity agreed on 6 Aug 2026.
Short interest spike: had 14.0M shares sold short in the 15 May 2026 report, 2.4× the same report last year Public on 28 May 2026.
Lobbying spend jump: reported $390K of lobbying spend for the quarter ended 30 Jun 2026, 2.8× the same quarter last year Public on 20 Jul 2026.
Reported lobbying spend: $280K in Q3 2026, $390K in Q2 2026. Rows are lobbying firms hired or let go; amounts are reported per quarter, not per firm here.
Date
Change
Lobbying firm
Issue
Source
31 Aug 2026
Ended
Forbes-Tatefor Ultragenyx Pharmaceutical
Issues related to drug development and market access.Health issues
Alpine Group Partners, LLC.for Ultragenyx Pharmaceutical Inc.
Monitoring FDA user fee regulation, including priority review voucher reauthorization; legislation around screening efforts for newborns and ultra-rare diseases like Duchenne Muscular Dystrophy (DMD) and Metachromatic Leukodystrophy (MLD)Health issues, Government issues, MED
Mehlman Consulting, Inc.for Ultragenyx Pharmaceutical, Inc.
Issues related to rare disease drug development and access; coverage for genetic testing; and newborn screening.Health issues, Budget, Medicare/Medicaid
Two or more unrelated kinds of records unusual within 30 days
6 Aug 2026confirmed
Confirmed across sources Filings + Financials and Lobbying and Short interest and volume
Ultragenyx Pharmaceutical(RARE): reported $390K of lobbying spend for the quarter ended 30 Jun 2026, 2.8× the same quarter last year; it also reported revenue of $214.0M for the quarter ended 30 Jun 2026, 1.3× the same quarter last year; and it had 15.0M shares sold short in the 31 Jul 2026 report, 2.0× the same report last year. Three unrelated kinds of activity within 29 days.
Lobbying: Lobbying on a new issue, became public on 20 Jul 2026
Lobbying: Lobbying spend jump, became public on 20 Jul 2026
Financials: Quarterly revenue change, became public on 6 Aug 2026
Short interest and volume: Short interest spike, became public on 12 Aug 2026
The quarter ended 30 Jun 2026 against the 8 quarters before it.
this quarterearliernormal: $135KSee the evidence (4 changes)
Lobbying: Lobbying on a new issue became public on 20 Jul 2026
Ultragenyx Pharmaceutical lobbying on a new issue.
New
['GOV', 'MED']
Rule
only points whose every posting (and value revision) is at or before as_of
Field
issue_codes
Metric
lobbying.filings_count
Point id
4687383
Lobbying: Lobbying spend jump became public on 20 Jul 2026
Ultragenyx Pharmaceutical reported $390K of lobbying spend for the quarter ended 30 Jun 2026, 2.8× the same quarter last year.
This period
$390K (the quarter ended 30 Jun 2026)
Normal quarter (median of 8 earlier)
$135K
Typical spread (median absolute deviation)
$40K
How far from its usual level
+4.3
Same quarter last year
$140K
History used
2,373 days
the quarter ended 30 Jun 20268 earlier quartersnormal: $135K
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 6+ earlier periods, 730+ days of history and a value of at least $100K.
Financials: Quarterly revenue change became public on 6 Aug 2026
Ultragenyx Pharmaceutical reported revenue of $214.0M for the quarter ended 30 Jun 2026, 1.3× the same quarter last year.
This period
$214.0M (the quarter ended 30 Jun 2026)
Normal quarter (median of 8 earlier)
$153.5M
Typical spread (median absolute deviation)
$13.5M
How far from its usual level
+3.0
Same quarter last year
$166.5M
History used
3,652 days
the quarter ended 30 Jun 20268 earlier quartersnormal: $153.5M
Fires when the period is at least 3.0 robust standard deviations above the company's own median, with 6+ earlier periods, 540+ days of history and a value of at least $10.0M.
Short interest and volume: Short interest spike became public on 12 Aug 2026
Ultragenyx Pharmaceutical had 15.0M shares sold short in the 31 Jul 2026 report, 2.0× the same report last year.
This period
15.0M (the 31 Jul 2026 report)
Normal report (median of 24 earlier)
9.0M
Typical spread (median absolute deviation)
1.1M
How far from its usual level
+3.7
Same report last year
7.6M
History used
3,136 days
the 31 Jul 2026 report24 earlier reportsnormal: 9.0M
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
Several things at once means two or more unrelated kinds of records changed sharply within 30 days. Records that come from the same documents (for example filings and the financials taken from them) count as one kind.
10 Dec 2019confirmed
Confirmed across sources Filings + Financials and Lobbying
Ultragenyx Pharmaceutical(RARE): spent $5.0M on capital projects in the quarter ended 30 Sep 2019, 4.9× the same quarter last year, while it registered for federal lobbying for the first time in our data (Forbes-Tate). Two unrelated kinds of activity within 27 days.
Financials: Quarterly capital spending jump, became public on 12 Nov 2019
Lobbying: First lobbying registration, became public on 10 Dec 2019
The quarter ended 30 Sep 2019 against the 8 quarters before it.
this quarterearliernormal: $1.1MSee the evidence (2 changes)
Financials: Quarterly capital spending jump became public on 12 Nov 2019
Ultragenyx Pharmaceutical spent $5.0M on capital projects in the quarter ended 30 Sep 2019, 4.9× the same quarter last year.
This period
$5.0M (the quarter ended 30 Sep 2019)
Normal quarter (median of 8 earlier)
$1.1M
Typical spread (median absolute deviation)
$239K
How far from its usual level
+3.9
Same quarter last year
$1.0M
History used
2,374 days
the quarter ended 30 Sep 20198 earlier quartersnormal: $1.1M
Fires when the period is at least 3.0 robust standard deviations above the company's own median, with 6+ earlier periods, 540+ days of history and a value of at least $5.0M.
"First" means first in our data: it fires only when the source's history began at least 365 days earlier.
Several things at once means two or more unrelated kinds of records changed sharply within 30 days. Records that come from the same documents (for example filings and the financials taken from them) count as one kind.
Timeline
Changes and notable records, by the date each became public
had 15.0M shares sold short in the 31 Jul 2026 report, 2.0× the same report last year.
Same report last year: 7.6M; its normal report is 9.0M.
See the evidence
This period
15.0M (the 31 Jul 2026 report)
Normal report (median of 24 earlier)
9.0M
Typical spread (median absolute deviation)
1.1M
How far from its usual level
+3.7
Same report last year
7.6M
History used
3,136 days
the 31 Jul 2026 report24 earlier reportsnormal: 9.0M
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
reported $390K of lobbying spend for the quarter ended 30 Jun 2026, 2.8× the same quarter last year; it also reported revenue of $214.0M for the quarter ended 30 Jun 2026, 1.3× the same quarter last year; and it had 15.0M shares sold short in the 31 Jul 2026 report, 2.0× the same report last year. Three unrelated kinds of activity within 29 days.
See the evidence (4 changes)
Lobbying: Lobbying on a new issue became public on 20 Jul 2026
Ultragenyx Pharmaceutical lobbying on a new issue.
New
['GOV', 'MED']
Rule
only points whose every posting (and value revision) is at or before as_of
Field
issue_codes
Metric
lobbying.filings_count
Point id
4687383
Lobbying: Lobbying spend jump became public on 20 Jul 2026
Ultragenyx Pharmaceutical reported $390K of lobbying spend for the quarter ended 30 Jun 2026, 2.8× the same quarter last year.
This period
$390K (the quarter ended 30 Jun 2026)
Normal quarter (median of 8 earlier)
$135K
Typical spread (median absolute deviation)
$40K
How far from its usual level
+4.3
Same quarter last year
$140K
History used
2,373 days
the quarter ended 30 Jun 20268 earlier quartersnormal: $135K
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 6+ earlier periods, 730+ days of history and a value of at least $100K.
Financials: Quarterly revenue change became public on 6 Aug 2026
Ultragenyx Pharmaceutical reported revenue of $214.0M for the quarter ended 30 Jun 2026, 1.3× the same quarter last year.
This period
$214.0M (the quarter ended 30 Jun 2026)
Normal quarter (median of 8 earlier)
$153.5M
Typical spread (median absolute deviation)
$13.5M
How far from its usual level
+3.0
Same quarter last year
$166.5M
History used
3,652 days
the quarter ended 30 Jun 20268 earlier quartersnormal: $153.5M
Fires when the period is at least 3.0 robust standard deviations above the company's own median, with 6+ earlier periods, 540+ days of history and a value of at least $10.0M.
Short interest and volume: Short interest spike became public on 12 Aug 2026
Ultragenyx Pharmaceutical had 15.0M shares sold short in the 31 Jul 2026 report, 2.0× the same report last year.
This period
15.0M (the 31 Jul 2026 report)
Normal report (median of 24 earlier)
9.0M
Typical spread (median absolute deviation)
1.1M
How far from its usual level
+3.7
Same report last year
7.6M
History used
3,136 days
the 31 Jul 2026 report24 earlier reportsnormal: 9.0M
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
Several things at once means two or more unrelated kinds of records changed sharply within 30 days. Records that come from the same documents (for example filings and the financials taken from them) count as one kind.
6 Aug 2026Financials change
reported revenue of $214.0M for the quarter ended 30 Jun 2026, 1.3× the same quarter last year.
Same quarter last year: $166.5M; its normal quarter is $153.5M.
See the evidence
This period
$214.0M (the quarter ended 30 Jun 2026)
Normal quarter (median of 8 earlier)
$153.5M
Typical spread (median absolute deviation)
$13.5M
How far from its usual level
+3.0
Same quarter last year
$166.5M
History used
3,652 days
the quarter ended 30 Jun 20268 earlier quartersnormal: $153.5M
Fires when the period is at least 3.0 robust standard deviations above the company's own median, with 6+ earlier periods, 540+ days of history and a value of at least $10.0M.
reported $390K of lobbying spend for the quarter ended 30 Jun 2026, 2.8× the same quarter last year.
Same quarter last year: $140K; its normal quarter is $135K.
See the evidence
This period
$390K (the quarter ended 30 Jun 2026)
Normal quarter (median of 8 earlier)
$135K
Typical spread (median absolute deviation)
$40K
How far from its usual level
+4.3
Same quarter last year
$140K
History used
2,373 days
the quarter ended 30 Jun 20268 earlier quartersnormal: $135K
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 6+ earlier periods, 730+ days of history and a value of at least $100K.
had 14.7M shares sold short in the 29 May 2026 report, 2.7× the same report last year.
Same report last year: 5.5M; its normal report is 8.6M.
See the evidence
This period
14.7M (the 29 May 2026 report)
Normal report (median of 24 earlier)
8.6M
Typical spread (median absolute deviation)
971K
How far from its usual level
+4.2
Same report last year
5.5M
History used
3,073 days
the 29 May 2026 report24 earlier reportsnormal: 8.6M
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
had 14.0M shares sold short in the 15 May 2026 report, 2.4× the same report last year.
Same report last year: 5.9M; its normal report is 8.5M.
See the evidence
This period
14.0M (the 15 May 2026 report)
Normal report (median of 24 earlier)
8.5M
Typical spread (median absolute deviation)
857K
How far from its usual level
+4.3
Same report last year
5.9M
History used
3,059 days
the 15 May 2026 report24 earlier reportsnormal: 8.5M
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
had 13.7M shares sold short in the 30 Apr 2026 report, 2.5× the same report last year.
Same report last year: 5.5M; its normal report is 8.4M.
See the evidence
This period
13.7M (the 30 Apr 2026 report)
Normal report (median of 24 earlier)
8.4M
Typical spread (median absolute deviation)
729K
How far from its usual level
+4.9
Same report last year
5.5M
History used
3,044 days
the 30 Apr 2026 report24 earlier reportsnormal: 8.4M
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
had 8.8M shares sold short in the 15 Jul 2025 report, 2.0× the same report last year.
Same report last year: 4.4M; its normal report is 4.2M.
See the evidence
This period
8.8M (the 15 Jul 2025 report)
Normal report (median of 24 earlier)
4.2M
Typical spread (median absolute deviation)
677K
How far from its usual level
+4.5
Same report last year
4.4M
History used
2,755 days
the 15 Jul 2025 report24 earlier reportsnormal: 4.2M
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
reported revenue of $164.9M for the quarter ended 31 Dec 2024, 1.3× the same quarter last year.
Same quarter last year: $127.4M; its normal quarter is $108.6M.
See the evidence
This period
$164.9M (the quarter ended 31 Dec 2024)
Normal quarter (median of 8 earlier)
$108.6M
Typical spread (median absolute deviation)
$9.3M
How far from its usual level
+4.1
Same quarter last year
$127.4M
History used
3,106 days
the quarter ended 31 Dec 20248 earlier quartersnormal: $108.6M
Fires when the period is at least 3.0 robust standard deviations above the company's own median, with 6+ earlier periods, 540+ days of history and a value of at least $10.0M.
reported revenue of $139.5M for the quarter ended 30 Sep 2024, 1.4× the same quarter last year.
Same quarter last year: $98.1M; its normal quarter is $105.8M.
See the evidence
This period
$139.5M (the quarter ended 30 Sep 2024)
Normal quarter (median of 8 earlier)
$105.8M
Typical spread (median absolute deviation)
$6.6M
How far from its usual level
+3.2
Same quarter last year
$98.1M
History used
3,014 days
the quarter ended 30 Sep 20248 earlier quartersnormal: $105.8M
Fires when the period is at least 3.0 robust standard deviations above the company's own median, with 6+ earlier periods, 540+ days of history and a value of at least $10.0M.
reported revenue of $147.0M for the quarter ended 30 Jun 2024, 1.4× the same quarter last year.
Same quarter last year: $108.3M; its normal quarter is $101.9M.
See the evidence
This period
$147.0M (the quarter ended 30 Jun 2024)
Normal quarter (median of 8 earlier)
$101.9M
Typical spread (median absolute deviation)
$6.6M
How far from its usual level
+4.4
Same quarter last year
$108.3M
History used
2,922 days
the quarter ended 30 Jun 20248 earlier quartersnormal: $101.9M
Fires when the period is at least 3.0 robust standard deviations above the company's own median, with 6+ earlier periods, 540+ days of history and a value of at least $10.0M.
reported $250K of lobbying spend for the quarter ended 31 Mar 2024, 5.0× the same quarter last year.
Same quarter last year: $50K; its normal quarter is $50K.
See the evidence
This period
$250K (the quarter ended 31 Mar 2024)
Normal quarter (median of 8 earlier)
$50K
Typical spread (median absolute deviation)
$0
How far from its usual level
+10.0
Same quarter last year
$50K
History used
1,552 days
the quarter ended 31 Mar 20248 earlier quartersnormal: $50K
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 6+ earlier periods, 730+ days of history and a value of at least $100K.
Showing the newest 40 of 81 entries; narrow the window or the kind of data to see older ones.
Not listed: 416 routine records (quarterly and annual reports, results releases, other 8-K items, material agreements and individual insider sales), counted over all history.
Identifiers and sources
How records are matched to this company, and what each source holds for it
Cik
0001515673
Ticker
RARE
Domain
ultragenyx.com
Employer name
Ultragenyx Pharmaceutical, Inc. (1 unverified)
Hq location
CA|NOVATO|94949 (1 unverified)
Lobbying client
ultragenyx, ultragenyx pharmaceutical
Name
Amlogenyx Inc, Rare Delaware Inc, Ultragenyx Argentina SRL, Ultragenyx Brasil Farmacêutica Ltda and 12 more
Uei
MS1ZFMTA7JH7
Wikipedia
Ultragenyx
DOL H-1B labor condition applications and PERM certifications309 data points6 Apr 2020 to 27 Jul 2026
Federal lobbying disclosures (LDA)14 records, 84 data points16 Oct 2019 to 30 Sep 2026
SEC Form 13F institutional holdings459 data points31 Mar 2014 to 30 Sep 2026
SEC EDGAR filings (8-K items, S-1, Form D, 10-K/10-Q)227 records25 Feb 2016 to 3 Nov 2026
SEC XBRL company facts (revenue, capex, R&D, backlog...)883 data points31 Dec 2011 to 29 Oct 2026
SEC Form 4 insider transactions219 records, 568 data points4 Jan 2016 to 19 Oct 2026
FINRA short interest (twice monthly)624 data points29 Dec 2017 to 30 Oct 2026
FINRA daily short sale volume (off-exchange)4178 data points1 Aug 2018 to 20 Nov 2026
Wikipedia pageviews11 data points11 Nov 2026 to 21 Nov 2026